409 related articles for article (PubMed ID: 12584586)
21. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
22. Prediction of aggressiveness of gastrointestinal stromal tumours based on immunostaining with bcl-2, Ki-67 and p53.
Meara RS; Cangiarella J; Simsir A; Horton D; Eltoum I; Chhieng DC
Cytopathology; 2007 Oct; 18(5):283-9. PubMed ID: 17883690
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
[TBL] [Abstract][Full Text] [Related]
24. Induction of apoptosis by monosaccharide butyrate stable derivatives in chronic lymphocytic leukemia cells.
Santini V; Gozzini A; Scappini B; Caporale R; Zoccolante A; Rigacci L; Gelardi E; Grossi A; Alterini R; Ferrini PR
Haematologica; 1999 Oct; 84(10):897-904. PubMed ID: 10509037
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
26. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer.
Yip KW; Shi W; Pintilie M; Martin JD; Mocanu JD; Wong D; MacMillan C; Gullane P; O'Sullivan B; Bastianutto C; Liu FF
Clin Cancer Res; 2006 Oct; 12(19):5726-32. PubMed ID: 17020977
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer.
Neri A; Marrelli D; Roviello F; DeMarco G; Mariani F; DeStefano A; Megha T; Caruso S; Corso G; Cioppa T; Pinto E
Breast Cancer Res Treat; 2006 Sep; 99(1):77-83. PubMed ID: 16541314
[TBL] [Abstract][Full Text] [Related]
29. Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
Morabito F; Filangeri M; Callea I; Sculli G; Callea V; Fracchiolla NS; Neri A; Brugiatelli M
Haematologica; 1997; 82(1):16-20. PubMed ID: 9107076
[TBL] [Abstract][Full Text] [Related]
30. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
31. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer.
Porebska I; Wyrodek E; Kosacka M; Adamiak J; Jankowska R; Harłozińska-Szmyrka A
In Vivo; 2006; 20(5):599-604. PubMed ID: 17091766
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques.
Marschitz I; Tinhofer I; Hittmair A; Egle A; Kos M; Greil R
Am J Clin Pathol; 2000 Feb; 113(2):219-29. PubMed ID: 10664624
[TBL] [Abstract][Full Text] [Related]
34. Aberrant nuclear p53 expression predicts hemizygous 17p (TP53) deletion in chronic lymphocytic leukemia.
Chang H; Jiang AM; Qi CX
Am J Clin Pathol; 2010 Jan; 133(1):70-4. PubMed ID: 20023260
[TBL] [Abstract][Full Text] [Related]
35. Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics.
Kalomenidis I; Orphanidou D; Papamichalis G; Vassilakopoulos T; Scorilas A; Rasidakis A; Papastamatiou H; Jordanoglou J; Roussos C
Lung; 2001; 179(5):265-78. PubMed ID: 11976895
[TBL] [Abstract][Full Text] [Related]
36. Significantly different bcl-2 expression profiles in gastric and non-gastric primary extranodal high-grade B-cell lymphomas.
Cogliatti SB; Griesser H; Peng H; Du MQ; Isaacson PG; Zimmermann DR; Maibach RC; Schmid U
J Pathol; 2000 Dec; 192(4):470-8. PubMed ID: 11113864
[TBL] [Abstract][Full Text] [Related]
37. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
[TBL] [Abstract][Full Text] [Related]
38. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
39. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of biological variables in B-cell chronic lymphocytic leukemia. Can we improve upon clinical parameters?
Molica S
Haematologica; 1997; 82(6):705-9. PubMed ID: 9499672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
